Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Agulnik
Northwestern University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- Northwestern University- Lake Forest Hospital
Lake Forest, Illinois, United States
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Mar 2015
- Primary completion
- 27 Apr 2018
- Completion
- 12 Oct 2021
- Last update posted
- 7 Jun 2022
- Registered enrollment
- 178
- Registry id
- NCT02357810
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.